Key Takeaways
- Definition: Peptide hormones are amino acid chains secreted by endocrine cells that act on distant target tissues through cell-surface receptors, initiating intracellular signaling cascades.
- Range of sizes: From 3 amino acids (thyrotropin-releasing hormone) to 191 amino acids (growth hormone); function derives from sequence, not size.
- Major examples: Insulin, glucagon, GLP-1, growth hormone, oxytocin, vasopressin, ghrelin, and PYY are among the most extensively characterized peptide hormones.
- Mechanism contrast: Peptide hormones act at cell surfaces; steroid hormones cross membranes and act on nuclear receptors — a distinction with major pharmacological consequences.
- Measurement: Most peptide hormone activity is measured indirectly through downstream markers: IGF-1 for GH axis activity, fasting insulin and glucose for insulin-glucagon balance, HbA1c for integrated glycemic exposure.
- Scope: This article covers endogenous peptide hormones produced by the body and FDA-approved peptide pharmaceuticals. It does not cover compounded or unapproved peptide compounds (e.g., BPC-157, CJC-1295, ipamorelin, TB-500), which are discussed separately and carry distinct regulatory status.
What Peptide Hormones Are
Peptide hormones are signaling molecules composed of amino acid chains, synthesized in specialized endocrine cells, secreted into the bloodstream, and acting on target tissues through specific cell-surface receptors. They are produced by the same ribosomal translation machinery that makes all proteins, initially as longer precursor molecules that are processed by proteolytic cleavage in the secretory pathway. The resulting mature hormone circulates at picomolar to nanomolar concentrations, binds its receptor with high specificity, and triggers a cascade of intracellular events that produce a biological response ranging from glucose uptake to uterine contraction to appetite suppression.
The defining mechanistic feature that distinguishes peptide hormones from steroid hormones is their inability to cross cell membranes. Peptides are water-soluble and too large and polar to diffuse through the lipid bilayer. They interact exclusively with cell-surface receptors, most commonly G protein-coupled receptors (GPCRs) or receptor tyrosine kinases. Choi and Bai, writing in the Annual Review of Biochemistry in 2023, reviewed the mechanism of peptide hormone-receptor activation at the structural level, showing how receptor binding induces conformational changes that activate downstream signaling. This extracellular action makes peptide hormone receptors highly accessible targets for drug design: a synthetic analog of the peptide hormone can activate, block, or modulate the receptor from outside the cell without needing to enter it.
Discovery and history
The history of peptide hormones as a discipline is largely the history of endocrinology. Secretin, discovered by Bayliss and Starling in 1902, was the first substance described as a hormone and was later found to be a 27-amino-acid peptide. Insulin, discovered by Banting and Best in 1921 and available as a clinical therapy by 1922, became the most consequential peptide hormone in medicine. Lewis and Brubaker, writing in the Journal of Clinical Investigation in 2021, reviewed the historical narrative of insulin's discovery and its transformation of type 1 diabetes from a fatal disease to a manageable condition. Wewer Albrechtsen and colleagues, in a century-long review of glucagon since its 1922 discovery in Diabetologia in 2023, traced how understanding of the second pancreatic peptide hormone evolved over 100 years from its initial description to its contemporary pharmacological roles.
How Peptide Hormones Work
The mechanism of peptide hormone action proceeds through three steps: secretion from the producing cell, circulation in the bloodstream, and receptor-mediated activation of target cell signaling. Each step is regulated and can be modified by disease or pharmacological intervention.
Synthesis, processing, and secretion
Peptide hormones are synthesized as larger precursors called prepropeptides or prohormones. Signal peptides at the N-terminus direct the nascent protein chain into the endoplasmic reticulum lumen, where the signal is cleaved to generate a propeptide. Further processing in the Golgi apparatus and secretory granules — by serine endoproteases such as prohormone convertases PC1 and PC2 — generates the mature, biologically active hormone. These processing steps are tissue-specific: the glucagon gene's product, proglucagon, is processed to glucagon in pancreatic alpha cells, but to GLP-1 and GLP-2 in intestinal L-cells and certain brainstem neurons, depending on which processing enzymes are expressed. Sandoval and D'Alessio, writing in Physiological Reviews in 2015, covered proglucagon-derived peptide hormones — glucagon, GLP-1, and GLP-2 — establishing how tissue-specific processing of a single precursor creates three peptides with distinct biological roles.
Secretion is stimulus-coupled: beta cells release insulin in response to elevated blood glucose; intestinal L-cells release GLP-1 and PYY after nutrient ingestion; somatotroph cells release growth hormone in response to GHRH pulses from the hypothalamus, primarily during deep sleep. Each secretory pattern is physiologically appropriate to the hormone's function.
Receptor binding and intracellular signaling
Peptide hormones bind their receptors at the extracellular face of the plasma membrane. Most peptide hormone receptors are GPCRs — seven-transmembrane proteins that couple to heterotrimeric G proteins upon agonist binding. Ligand binding induces conformational change in the receptor, activating the associated G protein, which in turn activates downstream effectors including adenylyl cyclase (increasing cyclic AMP) or phospholipase C (generating diacylglycerol and inositol trisphosphate). These second messengers activate downstream kinases, regulate ion channels, and alter gene expression, producing the biological response appropriate to the hormone and cell type.
The insulin receptor is a receptor tyrosine kinase rather than a GPCR. Upon insulin binding, the receptor autophosphorylates specific tyrosine residues and phosphorylates downstream substrates including IRS-1, activating the PI3K-Akt pathway that mediates insulin's metabolic effects. Sylow, Tokarz, Richter, and Klip, writing in Cell Metabolism in 2021, reviewed insulin's wide-ranging peripheral actions, covering glucose uptake, glycogen synthesis, lipid metabolism, and protein synthesis — all mediated through this single receptor tyrosine kinase cascade. Donnelly, writing in the British Journal of Pharmacology in 2012, reviewed GLP-1 receptor and ligand structure-function relationships, illustrating how the 30-amino-acid GLP-1 peptide engages its receptor to produce the insulin-stimulatory, glucagon-suppressive, and satiety-signaling responses that underlie the GLP-1 drug class.
Clearance and half-life
Most peptide hormones have short plasma half-lives ranging from a few minutes (native GLP-1: approximately 2 minutes due to DPP-IV cleavage) to tens of minutes (insulin: approximately 4–6 minutes). Clearance occurs through receptor-mediated endocytosis, proteolytic degradation by specific peptidases (DPP-IV cleaves GLP-1; insulin-degrading enzyme cleaves insulin), and renal filtration for small peptides. The short half-life of native peptide hormones is why most FDA-approved peptide drugs incorporate chemical modifications: semaglutide's C-18 fatty acid chain and albumin-binding domain extend its half-life to approximately one week; teriparatide (a PTH fragment) is given as a once-daily injection because modifications extend its usable duration sufficiently for clinical dosing. Drucker, in Nature Reviews Drug Discovery in 2020, reviewed how peptide drugs overcome GI barriers and circulatory clearance through structural modifications — the direct pharmacological application of understanding peptide hormone clearance mechanisms.
Major Categories of Peptide Hormones
Peptide hormones can be organized by their origin, their primary signaling axis, or their clinical significance. The following categories cover the most clinically and pharmacologically relevant groups.
- Pancreatic peptide hormones — insulin and glucagon:
- Origin and structure: Produced by beta cells (insulin, 51 amino acids) and alpha cells (glucagon, 29 amino acids) of the pancreatic islets of Langerhans.
- Primary signaling role: Counter-regulatory control of blood glucose: insulin promotes glucose uptake and storage; glucagon mobilizes glucose from glycogen stores during fasting.
- Where the research stands: Among the most thoroughly characterized peptide hormones in medicine. Andersen and Holst, writing in Peptides in 2022, reviewed how insulin regulates glucagon, showing the two hormones form an integrated regulatory pair. Müller, Finan, Clemmensen, and colleagues, in Physiological Reviews in 2017, provided a detailed review of glucagon biology and pharmacology.
- Incretin peptide hormones — GLP-1 and GIP:
- Origin and structure: GLP-1 (30 amino acids) and GIP (42 amino acids) are produced by intestinal L-cells and K-cells respectively in response to nutrient ingestion.
- Primary signaling role: Glucose-dependent stimulation of insulin secretion, GLP-1-mediated suppression of glucagon, gastric emptying delay, and appetite suppression. GIP primarily potentiates insulin but also has roles in adipose tissue and bone.
- Where the research stands: GLP-1's biology underpins one of the most commercially prominent classes of peptide drugs in modern pharmaceutical practice. Capozzi, D'Alessio, and Campbell, writing in Cell Metabolism in 2022, reviewed glucagon biology complementary to incretin signaling. Hædersdal and colleagues, in Nature Reviews Endocrinology in 2023, covered glucagon's contemporary metabolic roles.
- Pituitary and hypothalamic peptide hormones — GH and oxytocin:
- Origin and structure: Growth hormone (191 amino acids) is produced by anterior pituitary somatotrophs. Oxytocin (9 amino acids) and vasopressin (9 amino acids) are produced in hypothalamic nuclei and released from the posterior pituitary.
- Primary signaling role: GH stimulates IGF-1 production, lean mass, and fat metabolism. Oxytocin regulates parturition, lactation, and social behavior. Vasopressin controls water reabsorption in the kidney.
- Where the research stands: Gimpl and Fahrenholz, in Physiological Reviews in 2001, provided a widely cited review of oxytocin receptor biology. Rigney and colleagues, writing in Endocrinology in 2022, reviewed the structural similarities between oxytocin and vasopressin — both 9-amino-acid peptides sharing 7 of 9 residues — as a model for peptide hormone family homology. Reiss and colleagues, writing in Peptides in 2019, noted oxytocin's metabolic effects including effects on fat mass and glucose tolerance, illustrating the cross-system physiological reach of peptide hormones.
- Gut peptide hormones — ghrelin and PYY:
- Origin and structure: Ghrelin (28 amino acids) is produced in gastric oxyntic cells; PYY (36 amino acids as PYY1–36; circulates predominantly as the DPP-IV-cleaved PYY3–36 after meals) is produced in intestinal L-cells alongside GLP-1. Both circulate as appetite regulators.
- Primary signaling role: Ghrelin is orexigenic (appetite-stimulating), rising before meals and falling after. PYY is anorexigenic (appetite-suppressing), rising after meals in proportion to caloric intake and fat content. Hong and Choi, writing in Current Opinion in Endocrinology, Diabetes and Obesity in 2024, reviewed gut peptide hormones including ghrelin, PYY, and GLP-1 in appetite control. Pradhan, Samson, and Sun, writing in Current Opinion in Clinical Nutrition and Metabolic Care in 2013, reviewed ghrelin as a 28-amino-acid peptide hormone with multiple roles beyond appetite stimulation, including GH secretagogue activity.
- Where the research stands: Ghrelin and PYY are the subject of active pharmaceutical research as appetite-regulating signals, with ongoing investigation of their roles in combination therapy contexts.
What the Evidence Shows
The evidence for peptide hormone biology is among the most robust in endocrinology, reflecting decades of mechanistic study and large-scale clinical trials. The foundational mechanisms — receptor binding, G protein activation, downstream kinase cascades — are well characterized for the major hormones. The clinical evidence for pharmacological manipulation of peptide hormone systems is equally strong for certain classes.
Insulin-glucagon system: among the most extensively studied peptide hormone pairs
Insulin's biology has been characterized continuously since 1921. Modern cryo-EM studies by Lawrence, published in Molecular Metabolism in 2021, resolved the atomic-level interactions between insulin and its receptor at angstrom resolution, providing structural context for a century of pharmacological data. The counter-regulatory role of glucagon was formalized over the same period. Andersen and Holst, writing in Peptides in 2022, showed how insulin regulates glucagon secretion through direct paracrine signaling within the islet — demonstrating that the two peptide hormones form an integrated feedback pair. Understanding this pair is essential to understanding both type 1 and type 2 diabetes, where the ratio of these two peptide hormones determines the moment-to-moment glycemic state.
GLP-1: peptide hormone turned drug target
The conversion of GLP-1 from a physiological peptide hormone to a drug class represents a commercially significant episode in modern peptide pharmacology. Andersen, Lund, Knop, and Vilsbøll, writing in Nature Reviews Endocrinology in 2018, provided a comprehensive review of GLP-1 biology including the incretin effect, receptor distribution, and the pharmacological modifications that extended its half-life from minutes to days. The clinical evidence for GLP-1 receptor agonists — including the SUSTAIN, LEADER, and STEP trial programs — represents an extensive human trial data record for a peptide hormone-based drug class. As of April 2026, semaglutide holds FDA approvals for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), with cardiovascular outcome trial data from the SELECT trial showing a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes; the FLOW trial (Perkovic et al., NEJM 2024) demonstrated renal-outcome benefits in patients with type 2 diabetes and chronic kidney disease. References to semaglutide, liraglutide, and tirzepatide in this article refer to the FDA-approved products (Ozempic, Wegovy, Saxenda, Mounjaro, Zepbound, Rybelsus). Compounded versions of these peptides are not the FDA-approved products and, following resolution of the FDA-declared shortages in 2024–2025, are generally subject to the "essentially a copy" prohibitions at FDCA § 353a(b)(2) (for 503A pharmacies) and § 353b(a)(5) (for 503B outsourcing facilities), absent a documented clinical difference for the individual patient.
Evidence gaps and limitations
Despite extensive characterization of major peptide hormones, significant gaps remain. The long-term effects of pharmacological manipulation of peptide hormone systems — including chronic GLP-1 receptor agonism — are still being characterized through ongoing pharmacovigilance and post-approval studies. The roles of less-studied peptide hormones, including many of the gut hormones (PYY3-36, GIP, oxyntomodulin) in the context of combination therapy, remain active research areas. As of April 2026, long-term safety data (beyond 5–7 years) for the newer peptide hormone analogs in chronic weight-management indications — particularly high-dose semaglutide and tirzepatide in non-diabetic populations — are still being generated through ongoing pharmacovigilance and post-approval studies. Older peptide hormone analogs, such as insulin analogs, have multi-decade post-marketing safety records.
How Peptide Hormones Connect to Measurable Biomarkers
Peptide hormones are rarely measured directly in clinical practice; their activity is typically inferred from the downstream markers they regulate. This is partly because most peptide hormones have short half-lives that make single-point measurement unreliable, and partly because the downstream markers are more clinically actionable.
- Insulin: Fasting insulin reflects basal insulin secretion and the degree of insulin resistance — the downstream state most determined by years of insulin-glucagon system activity. Elevated fasting insulin often precedes clinical hyperglycemia by years and is among the earliest detectable signals of metabolic dysfunction.
- Glucose: Fasting glucose is the primary direct readout of the insulin-glucagon balance at rest. The ratio of insulin to glucagon signaling determines whether the liver is storing glucose as glycogen or releasing it into the circulation.
- HbA1c: A 90-day integrated measure of glycemic exposure, HbA1c is the primary endpoint for assessing insulin-glucagon system function over time and the standard clinical outcome measure in most GLP-1 peptide drug trials.
- IGF-1: The primary downstream marker of growth hormone peptide hormone activity. IGF-1 reflects the integrated GH secretory pattern over days and is more clinically useful for GH axis assessment than single GH measurements. Both GH deficiency and GH excess (acromegaly) are diagnosed through IGF-1 and dynamic testing.
- Triglycerides: Reflect the downstream effects of insulin-glucagon balance on hepatic fat metabolism. Insulin promotes triglyceride synthesis and inhibits lipolysis; glucagon has opposing effects. Elevated fasting triglycerides often indicate impaired insulin signaling in the metabolic context of insulin resistance.
For anyone exploring the biology of the GLP-1 receptor agonist drug class, understanding the endogenous peptide hormone these drugs mimic — and the downstream markers that track its effects — provides the scientific foundation for interpreting clinical measurements. The biomarkers relevant to metabolic health and weight loss directly reflect peptide hormone system activity.
When to Take This Seriously
Symptoms that can reflect peptide hormone system abnormalities — persistent elevated blood sugar, abnormal thirst or urination, unusual changes in appetite, and slowed recovery from physical exertion — each correspond to established endocrine evaluation pathways. These are not vague symptoms; they are signals that specific peptide hormone systems may be operating outside normal range. The relevant clinical evaluation starts with bloodwork: fasting insulin, glucose, HbA1c, and IGF-1 provide direct context for the four most clinically significant peptide hormone axes in metabolic and endocrine medicine.
Understanding that what your bloodwork measures are the downstream effects of peptide hormone activity — that a high fasting insulin reflects the insulin-glucagon system under strain, and that an elevated HbA1c reflects months of elevated glucose exposure, which for many people is downstream of impaired insulin secretion, insulin resistance, and diminished incretin signaling — reframes what those numbers mean. That biological grounding is central to Superpower's approach to preventive health: objective data, understood in its molecular context, is a clear starting point for any health decision.
IMPORTANT SAFETY INFORMATION
Semaglutide is an FDA-approved prescription medication available as Wegovy (chronic weight management), Ozempic (type 2 diabetes), and Rybelsus (oral formulation for type 2 diabetes).
Compounded semaglutide is not the FDA-approved product; as of April 2026 the FDA-declared shortage has resolved, and 503A/503B compounding of a drug that is essentially a copy of the commercially available approved product is generally prohibited under FDCA § 353a(b)(2) (for 503A pharmacies) and § 353b(a)(5) (for 503B outsourcing facilities) absent a documented clinical difference for the individual patient.
Contraindications: personal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2; known hypersensitivity to semaglutide. Warnings: thyroid C-cell tumors in rodents (human relevance unknown at current follow-up); pancreatitis; hypoglycemia in combination with insulin or sulfonylureas; acute kidney injury; hypersensitivity reactions; diabetic retinopathy; suicidal ideation. Common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain.
Tirzepatide is an FDA-approved prescription medication available as Zepbound (chronic weight management; and, since December 2024, moderate-to-severe obstructive sleep apnea in adults with obesity) and Mounjaro (type 2 diabetes). Compounded tirzepatide is not the FDA-approved product; as of April 2026 the FDA-declared shortage has resolved, and 503A/503B compounding of a drug that is essentially a copy of the commercially available approved product is generally prohibited under FDCA § 353a(b)(2) (for 503A pharmacies) and § 353b(a)(5) (for 503B outsourcing facilities) absent a documented clinical difference for the individual patient. Contraindications and warnings similar in class to semaglutide above.
Liraglutide, teriparatide, insulin analogs, oxytocin (Pitocin), and other FDA-approved peptide medications referenced in this article are available only under the supervision of licensed healthcare providers for their FDA-approved indications. Full prescribing and safety information for approved peptide products is available at dailymed.nlm.nih.gov.
This article does not cover compounded or unapproved peptide compounds (e.g., BPC-157, CJC-1295, ipamorelin, TB-500); those compounds have distinct regulatory status and are discussed separately.
